Dis Colon Rectum. 2023 Jun 20. doi: 10.1097/DCR.0000000000002686. Online ahead of print.
ABSTRACT
BACKGROUND: The association of micropapillary pattern with oncologic outcomes has not been fully studied in patients with colon cancer.
OBJECTIVE: We evaluated the prognostic value of micropapillary pattern, especially for patients with stage II colon cancer.
DESIGN: A retrospective comparative cohort study using propensity score matching.
SETTING: This study was conducted at a single tertiary center.
PATIENTS: The patients with primary colon cancer undergoing curative resection from October 2013 to December 2017 were enrolled. The patients were grouped into micropapillary pattern (+) or micropapillary pattern (-).
MAIN OUTCOME MEASUREMENTS: Disease-free survival and overall survival.
RESULTS: Of the eligible 2,192 patients, 334 (15.2%) were micropapillary pattern (+). After 1:2 propensity score matching, 668 patients with micropapillary pattern (-) were selected. Micropapillary pattern (+) group showed significantly worse 3-year disease-free survival (77.6% vs. 85.1%, p = 0.007). Three-year overall survival of micropapillary pattern-positive and micropapillary pattern-negative did not show a statistically significant difference (88.9% vs. 90.4%, p = 0.480). In multivariable analysis, micropapillary pattern -positive was an independent risk factor for poor disease-free survival (hazard ratio 1.547, p = 0.008). In the subgroup analysis for 828 patients with stage II disease, 3-year disease-free survival deteriorated significantly in micropapillary pattern (+) patients (82.6% vs. 93.0, p < 0.001). Three-year overall survival was 90.1% and 93.9% in micropapillary pattern (+) and micropapillary pattern (-), respectively (p = 0.082). In the multivariable analysis for patients with stage II disease, micropapillary pattern (+) was an independent risk factor for poor disease-free survival (hazard ratio 2.003, p = 0.031).
LIMITATIONS: Selection bias due to the retrospective nature of the study.
CONCLUSIONS: Micropapillary pattern (+) may serve as an independent prognostic factor for colon cancer, especially for patients with stage II disease.
PMID:37339285 | DOI:10.1097/DCR.0000000000002686
